Comstock Resources (CRK) Announces $28M Sale of South Texas Nat Gas Properties
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Comstock Resources, Inc. (NYSE: CRK) announced that it has entered into a definitive purchase and sale agreement with a third party to sell Comstock's conventional natural gas properties in South Texas for a sale price of $28.0 million. The sale, which is subject to customary closing conditions and adjustments, is expected to close in December 2016 and will have an effective date of August 1, 2016. Comstock intends to use the proceeds from the sale toward funding its 2016 drilling program.
The properties being sold are producing approximately 9.6 million cubic feet per day of natural gas and 22 barrels of oil per day. At September 30, 2016, Comstock's proved reserves included approximately 57,000 barrels of oil and 48.9 billion cubic feet of natural gas related to the interests being sold. The Company expects to realize a pre-tax loss on the divestiture of approximately $10.0 million.
The Company also announced that it has recently restarted its Haynesville drilling program and on September 28th spudded the Company's fourth well this year and plans to add a second operated drilling rig by early November.
Additionally, Comstock has begun to implement its hedging program for 2017 with the recent improvement in natural gas prices. Currently, the Company has hedged 30 million cubic feet per day of its 2017 natural gas production at $3.25 per Mmbtu.
"This sale strengthens our balance sheet by providing additional liquidity and helps fund our Haynesville shale drilling program," stated M. Jay Allison, Chief Executive Officer of Comstock.
BMO Capital Markets served as exclusive financial advisor and Locke Lord LLP served as legal advisor to Comstock on the transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Athene Holding (ATH) Prices 27M Share IPO Inline with Prior Expectations
- Allergan (AGN) Receives Unfavorable PTAB Decision on RESTASIS-Related IPRs
- Northwest Biotherapeutics (NWBO) Offers Update on Phase 3 Trial Of DCVax-L for Newly Diagnosed GBM Cancer
Create E-mail Alert Related CategoriesCorporate News, Management Comments, Spinoffs
Related EntitiesBMO Capital, Haynesville Shale
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!